This article reviews recent developments in the design of polyvalent ligands for in vivo applications. Topics discussed include the design of polyvalent inhibitors of toxins and viruses, the use of polyvalency for targeted drug delivery and imaging, and applications of polyvalency for enhancing or suppressing immune responses.
No takes yet. Share an insight, caveat, or question.
Joshi et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: